Studies of targeted therapies in PNET have, to date, focused primarily on inhibitors of the vascular endothelial growth factor (VEGF) or mammalian target of rapamycin- (mTOR) signaling pathways. Here, MTOR is linked to primitive neuroectodermal tumor.